64 results about "Obstructive chronic bronchitis" patented technology

The invention relates to the technical field of traditional Chinese medicine, in particular to a Mongolian medicine tea drink for relieving respiratory system abnormality and a preparation method and application thereof.The Mongolian medicine tea drink is prepared from rhododendron micranthum, pomegranate, amomum cardamomum, long pepper, cinnamon, safflower, agilawood, clove, myristica fragrans, fructus choerospondiatis, bistort rhizome, liquorice, tabasheer, radix aucklandiae, white raisin and crabs. The processed products of the Mongolian medicine components are weighed according to the formula dosage, then ground into coarse powder and bagged to prepare tea bags. The Mongolian medicine tea drink provided by the invention has the effects of moving Heli, relieving cough, reducing phlegm and diminishing swelling; the traditional Chinese medicine composition can be used for treating the symptoms such as' Bada dry Hiri 'dizziness, asthma, chronic bronchitis, indigestion disease, edema, edema and water tympanites.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

Provided herein are pharmaceutical compositions and methods for treating COPD or COPD exacerbations in subjects suffering from, for example, moderate COPD, or subjects with decreased eosinophil concentrations, or are suffering from chronic bronchitis. Also provided herein are methods of increasing trough lung function in subjects suffering from moderate COPD. In some aspects, the compound is in an inhalable pharmaceutical composition.

Provided herein are pharmaceutical compositions and methods for treating COPD or COPD exacerbations in subjects suffering from, for example, moderate COPD, or subjects with decreased eosinophil concentrations, or are suffering from chronic bronchitis. Also provided herein are methods of increasing trough lung function in subjects suffering from moderate COPD.

The invention discloses a back cumin treatment method which is used for relieving symptoms of patients with chronic obstructive pulmonary disease and chronic bronchitis. The method comprises the following steps: preparing a cumin ground medicine which comprises 9g of viola tianshanica, 9g of hollyhock seed, 9g of common fenugreek seed, 9g of dill seed, 9g of linseed, 9g of chamomile, 100g of sesame oil or olive oil and other materials, blending the medicine and oil or warm boiled water into a paste at 38-40 DEG C, applying the paste to lung positions (15 * 20cm, 0.3-0.5 cm in thickness) on two sides of the back of a patient, covering the lung positions with a preservative film, irradiating the lung positions with a TDP baking lamp which is not less than 20cm in height for 20-30 minutes, and cleaning the medicine applying positions after the process is finished. Viola tianshanica in the cumin geomedicine can clear away heat and toxic materials, diminish inflammation and relieve pain, hollyhock seeds can clear heat and induce diuresis, and relieve cough and asthma, through the treatment, the medicine efficiently permeates and quickly acts on diseased regions, the symptoms of patients are effectively relieved, and the life quality is improved.

The present invention discloses a traditional Chinese medicine composition for treating chronic bronchitis combined with emphysema. The composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus, 20-30 parts of prepared rehmannia, 18-22 parts of schisandra, 15-25 parts of pinellia, and 20-30 parts of poria. The composition nourishes the liver, spleen, and kidneys, reduces stomach qi, purges the lungs, and relieves asthma, promotes diuresis and reduces swelling, promotes blood circulation and removes blood stasis, regulates qi and resolves phlegm, and is suitable for treating chronic bronchitis combined with emphysema. The present invention also discloses a preparation method and use thereof.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The invention relates to the technical field of traditional Chinese medicine preparations and atomization medicine delivery, in particular to a method for treating chronic bronchitis based on Tibetan medicine Bunjinjian San, which comprises the following steps: S1, drying Bunjinjian San raw medicine at low temperature, and carrying out superfine grinding to obtain raw medicine micro powder; s2, removing resin and grease impurities; s3, carrying out vacuum concentration on the obtained filtrate; s4, treating the concentrated extract through an ultrafiltration membrane; s5, preparing the clarified extracting solution into atomized liquid; s6, medicine aerosol is formed through ultrasonic oscillation; s7, guiding the chronic bronchitis patient to inhale the drug aerosol; s8, after all the inhalation treatment courses are completed, a treatment conclusion report is obtained. According to the present invention, the particle size controllable Bunjinjian aerosol is prepared through the continuous purification-clarification-sterilization-atomization process, such that the targeted lower respiratory tract drug delivery is achieved, the preparation quality and the equipment smoothness are ensured, the local treatment effect is improved, and the whole body side effect is reduced.

Systems and methods involve abrading a patient lung airway wall to reduce mucus production therein. Exemplary techniques include rotationally and / or linearly oscillating an abrasive material against the airway wall so as to damage mucus producing tissues, for example by removing goblet cells, while destroying less than the entire airway wall. The abrasive material may be present on the surface of an expandable balloon body or another expandable device, which can be delivered to the patient treatment site via a bronchoscope. In some cases, the abrasion techniques can cause cell damage or death at a controlled or predetermined tissue depth.

1. The name of the design product: water negative ion device. 2. The use of the design product: for air purification and disinfection, auxiliary treatment of chronic bronchitis and non-acute insomnia. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.

1. The name of the design product: lung instrument. 2. The use of the design product: for the auxiliary treatment of chronic bronchitis, chronic obstructive emphysema, bronchial asthma, and chronic pulmonary heart disease and other diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The present invention relates to novel pyrrolidinium compounds, stereoisomers, hydrates or solvates thereof, which exhibit excellent binding capacity and antagonistic activity to muscarinic receptors, in particular muscarinic M3 receptors. The compounds of the present invention are useful in the treatment of muscarinic acetylcholine receptor mediated diseases, such as hyperhidrosis, excessive salivation, chronic obstructive pulmonary disease, chronic bronchitis, asthma, rhinitis, urinary incontinence, overactive bladder, gastroesophageal reflux disease, irritable bowel syndrome, and the like.

A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.

The invention discloses a Tibetan medicine Banjiaojiaopian pellet preparation, which comprises raw materials and auxiliary materials, the raw materials comprise the following components: gentiana algida, agilawood, choerospondias axillaris, white sandalwood, myristica fragrans, tabasheer, alpine horseradish, costus root, fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit, tinospora sinensis merr, corydalis impatiens, clove and liquorice, and the auxiliary materials comprise an adhesive and a filler microcrystalline cellulose; the technological parameters for preparing the pellet preparation by adopting centrifugal granulation are as follows: the liquid spraying speed is 50ml / min, the number of revolutions of a turntable is 30r / min, and the air inlet temperature is 75 DEG C. Compared with traditional pills, the pellet preparation provided by the invention has the advantages of high dissolution rate, obviously improved bioavailability, reliable drug effect, accurate taking dosage, stable quality, low cost, good treatment effect, fine production process, good reproducibility, good quality controllability, high industrial production efficiency and wide application range.

The invention relates to the technical field of traditional Chinese medicine or food, and provides an application of a traditional Chinese medicine composition in preparation of a product for relieving and / or preventing lung heat and fluid impairment syndrome, the composition comprises the following components: orange peel, honeysuckle, mint, forsythia leaf, reed rhizome, platycodon grandiflorum, boat-fruited sterculia seed, lily, momordica grosvenori and almond. The composition provided by the invention has a remarkable effect of preventing chronic upper respiratory infection, a remarkable effect of treating oral ulcer caused by excessive internal heat, a remarkable effect of treating chronic pharyngolaryngitis and a remarkable effect of treating chronic bronchitis, and can be used for preparing products for relieving and / or preventing and treating lung heat and fluid impairment syndromes.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

The invention discloses a compound. The structural formula of the compound is shown in the specification. R is selected from-C (O) NR1R2,-N (R1) C (O) R2 and-C (O) R3; r1, R2 and R3 are respectively and independently selected from C1-C3 alkyl groups, 4-8-membered aryl groups, 4-8-membered heteroaryl groups and 4-10-membered heterocyclic groups, and the aryl groups can be further substituted by methyl and halogen. Cell experiments prove that the small molecule compound disclosed by the invention has a remarkable inhibition effect on TNF-alpha induced NF-kappa B signal activation, and has no obvious cytotoxicity. Animal experiments prove that the preferable compound has a remarkable improvement effect on the level of inflammatory factors in peripheral blood of a lipopolysaccharide-induced mouse sepsis model and the survival rate of mice. These compounds and pharmaceutical compositions are envisaged to be useful in the prevention or treatment of inflammatory diseases, such as sepsis, acute and chronic bronchitis, and the like. # imgabs0 #

The invention provides a traditional Chinese medicine extract for treating acute and chronic bronchitis and a preparation method thereof. The invention further provides a traditional Chinese medicine mixture and a preparation method thereof. The invention further provides traditional Chinese medicine granules and a preparation method thereof. The invention also provides application of the traditional Chinese medicine extract, the traditional Chinese medicine mixture or the traditional Chinese medicine granules in preparation of medicines for relieving cough, reducing phlegm and treating acute and chronic bronchitis. The invention further provides a method for determining multiple components in the traditional Chinese medicine preparation. The invention further provides a medicinal material attribution method of various components in the traditional Chinese medicine preparation. According to the traditional Chinese medicine granule for treating the acute and chronic bronchitis and the preparation, application and multi-component determination thereof, the prepared traditional Chinese medicine preparation, especially the traditional Chinese medicine granule, is suitable for people with cough, expectoration and the acute and chronic bronchitis, meanwhile, 81 components of the traditional Chinese medicine preparation, especially the traditional Chinese medicine granule can be qualitatively detected through the determination method, and the detection result is accurate. 13 components can be quantitatively detected.

Systems and methods involve abrading a patient lung airway wall to reduce mucus production therein. Exemplary techniques include rotationally and / or linearly oscillating an abrasive material against the airway wall so as to damage mucus producing tissues, for example by removing goblet cells, while destroying less than the entire airway wall. The abrasive material may be present on the surface of an expandable balloon body or another expandable device, which can be delivered to the patient treatment site via a bronchoscope. In some cases, the abrasion techniques can cause cell damage or death at a controlled or predetermined tissue depth.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating and / or preventing chronic bronchitis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 300 to 400 parts of cordia dichotoma fruits, 100 to 200 parts of Chinese dates, 150 to 200 parts of pericarpium papaveris, 50 to 100 parts of liquorice, 10 to 50 parts of hollyhock seeds, 10 to 50 parts of cucumber seeds, 10 to 50 parts of cydonia oblonga seeds, 50 to 100 parts of almonds, 50 to 100 parts of pericarpium papaveris, 10 to 50 parts of tragacanth gum, 10 to 50 parts of liquorice extract and 10 to 50 parts of Arabic gum.

The invention relates to the technical field of tracheitis treatment, in particular to a spittoon asthma tablet and a preparation method thereof. The tablets for treating asthma caused by excessive phlegm comprise 60-80 parts of radix sophorae flavescentis extract, 5-10 parts of golden cypress fruit oil, 20-30 parts of filler, 1-2 parts of lubricant, 5-10 parts of lily, 2-5 parts of fried almond and 0.5-1 part of liquorice. The sophora flavescens extract, the cortex phellodendri oil and the lily have a synergistic effect, and after the sophora flavescens extract, the cortex phellodendri oil and the lily are combined, cough and asthma such as chronic tracheitis or bronchitis can be remarkably treated, and the effect is remarkable.

The invention discloses a traditional Chinese medicine compound preparation and a preparation method thereof. The compound preparation is prepared from, by weight, 6-10 parts of herba ephedrae, 9-12 parts of semen armeniacae amarae, 6-9 parts of radix platycodonis, 9-15 parts of cortex mori, 6-10 parts of fritillary bulb, 10-15 parts of thorny elaeagnus leaf, 12-18 parts of herba ardisiae japonicae, 9-12 parts of folium eriobotryae, 15-30 parts of herba houttuyniae, 6-10 parts of caulis bambusae in taeniam, 6-9 parts of pericarpium citri reticulatae, 3-6 parts of spearmint and 3-6 parts of radix glycyrrhizae. The traditional Chinese medicine compound preparation disclosed by the invention creatively integrates the three effects of diffusing the lung, dispelling wind, clearing heat, reducing phlegm, moistening dryness and relieving asthma, and has a good effect in the aspect of treating exogenous cough with symptoms of acute and chronic bronchitis and cough after cold.

The invention belongs to the field of biological medicine, and particularly relates to application of small molecules in prevention and treatment of acute and chronic bronchitis, N-dodecyl methylamine can significantly prolong cough latency time of mice suffering from acute or chronic bronchitis, significantly reduce cough times of the mice suffering from acute or chronic bronchitis, and significantly improve cough latency time of the mice suffering from acute or chronic bronchitis. The micromolecule can be used as a medicine for treating or relieving acute or chronic bronchitis, and a new choice is provided for clinical treatment of bronchitis; double distilled water suspension small molecules are adopted for administration, the method is simple, convenient and rapid, and a remarkable effect is achieved. The micromolecule can obviously reduce the cough frequency and cough latency time of acute and chronic bronchitis, and has a good clinical application prospect.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

The present application relates to a use of L-erodostatin, and more particularly, to a use of erodostatin in preparation of a medicament, wherein the medicament is used for one or more of mucus dissolution and expectoration, treatment or improvement of upper respiratory inflammation, treatment or prevention of acute or chronic bronchitis, treatment or prevention of cough, treatment or prevention of asthma, treatment or prevention of pneumonia, prevention of pulmonary fibrosis, prevention of alveolar destruction, treatment or prevention of chronic obstructive pulmonary disease, enhancement of resistance to bacteria causing upper respiratory infection, and improvement of side effects caused by smoking. The present application can rapidly increase the blood concentration of metabolically active Met-I of erodostatin, exhibit a rapid and excellent effect, and has no toxicity, and has the same effect as the existing racemic compound at a smaller amount. In addition, since the amount used can be less than that of the existing racemic compound, the present application has an effect of reducing potential side effects.

The invention belongs to the technical field of medicines, and particularly discloses a novel 5-7-5 ring system beta acid compound, a preparation method thereof and application of the compound in preparation of anti-inflammatory drugs. The novel 5-7-5 ring system beta acid compound provided by the invention is obtained by separation in nature for the first time, and can be used for preparing medicines for treating inflammation-related diseases, including but not limited to chronic bronchitis, systemic lupus erythematosus, psoriatic arthritis, retinitis, neurological inflammation, rheumatoid arthritis and the like.